Noelia Martínez-Jáñez
Instituto Cajal(ES)Hospital Universitario de Canarias(ES)VA Puget Sound Health Care System(US)Instituto Ramón y Cajal de Investigación Sanitaria(ES)Vall d'Hebron Hospital Universitari(ES)Hospital Universitario Ramón y Cajal(ES)GEICAM – Spanish Breast Cancer Group(ES)
Publications by Year
Research Areas
Advanced Breast Cancer Therapies, HER2/EGFR in Cancer Research, Cancer Treatment and Pharmacology, Breast Cancer Treatment Studies, Lung Cancer Treatments and Mutations
Most-Cited Works
- → HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial(2017)336 cited
- → Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial(2020)211 cited
- → Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial(2021)153 cited
- → Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study(2015)132 cited
- → Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade(2020)117 cited